National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
Search
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI
Myelodysplastic/Myeloproliferative Diseases Treatment (PDQ®)
Patient VersionHealth Professional VersionEn españolLast Modified: 02/22/2008



General Information About Myelodysplastic/Myeloproliferative Diseases






Chronic Myelomonocytic Leukemia






Juvenile Myelomonocytic Leukemia






Atypical Chronic Myelogenous Leukemia






Myelodysplastic/Myeloproliferative Disease, Unclassifiable






Stages of Myelodysplastic/Myeloproliferative Diseases






Treatment Option Overview







Treatment Options for Myelodysplastic/Myeloproliferative Diseases






Get More Information From NCI






Changes to This Summary (02/22/2008)






About PDQ



Page Options
Print This Page  Print This Page
Print This Document  Print Entire Document
View Entire Document  View Entire Document
E-Mail This Document  E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

NIH Calendar of Events

Español
NCI Highlights
New Study of Targeted Therapies for Breast Cancer

The Nation's Investment in Cancer Research FY 2009

President's Cancer Panel Annual Report: 2006-2007

Cancer Trends Progress Report: 2007 Update

Past Highlights
HPV Vaccines for Cervical Cancer
Treatment Options for Myelodysplastic/Myeloproliferative Diseases

Chronic Myelomonocytic Leukemia
Juvenile Myelomonocytic Leukemia
Atypical Chronic Myelogenous Leukemia
Myelodysplastic/Myeloproliferative Disease, Unclassifiable



Chronic Myelomonocytic Leukemia

Treatment of chronic myelomonocytic leukemia (CMML) may include the following:

Information about ongoing clinical trials is available from the NCI Web site.

Check for clinical trials from NCI's PDQ Cancer Clinical Trials Registry that are now accepting patients with chronic myelomonocytic leukemia.

Juvenile Myelomonocytic Leukemia

Treatment of juvenile myelomonocytic leukemia (JMML) may include the following:

Information about ongoing clinical trials is available from the NCI Web site.

Check for clinical trials from NCI's PDQ Cancer Clinical Trials Registry that are now accepting patients with juvenile myelomonocytic leukemia.

Atypical Chronic Myelogenous Leukemia

Treatment of atypical chronic myelogenous leukemia (aCML) may include chemotherapy. Information about ongoing clinical trials is available from the NCI Web site.

Check for clinical trials from NCI's PDQ Cancer Clinical Trials Registry that are now accepting patients with atypical chronic myeloid leukemia.

Myelodysplastic/Myeloproliferative Disease, Unclassifiable

Because myelodysplastic /myeloproliferative disease, unclassifiable (MDS/MPD-UC) is a rare disease, little is known about its treatment. Supportive care treatments are used to manage problems caused by the disease such as infection, bleeding, and anemia.

Check for clinical trials from NCI's PDQ Cancer Clinical Trials Registry that are now accepting patients with myelodysplastic/myeloproliferative disease, unclassifiable.

Back to TopBack to Top

< Previous Section  |  Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov